In a report released on February 7, Benjamin Nolan from Stifel Nicolaus maintained a Buy rating on Capital Clean Energy Carriers (CCEC – ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Stifel Nicolaus analyst Cole McGill maintained a Buy rating on Critical Elements (CRECF – Research Report) today and set a price target of ...

Apple supplier Skyworks Solutions saw its stock drop nearly 25% Thursday as the semiconductor firm said that it's losing ...

Now that Groundhog Day has come and gone, the second half of winter is among us, which means all the weirdos start coming out ...

Matson, Inc. (NYSE: MATX) announced today that Matt Cox, Chairman and Chief Executive Officer will be attending the Stifel 2025 Transportation & Logistics Conference to be held on February 11, 2025 in ...

Shares in Infineon rose 11 per cent after the German chipmaker slightly upgraded its full-year revenue outlook and reported ...

Software developer Dassault Systemes on Tuesday forecast revenue growth of between 6 per cent and 8 per cent for 2025, up ...

BERLIN (Reuters) - Volkswagen is counting on talks to avoid trade conflict, Europe's biggest carmaker said on Sunday, after U ...

British pest control firm Rentokil Initial said on Tuesday its organic revenue grew 3% in the fourth quarter, led by faster ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...